Denali Therapeutics’ (DNLI) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report report published on Friday,Benzinga reports. They currently have a $32.00 price target on the stock.

Several other brokerages have also recently weighed in on DNLI. Wedbush dropped their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a report on Monday, November 17th. Morgan Stanley restated an “overweight” rating and set a $40.00 price target on shares of Denali Therapeutics in a report on Thursday, January 8th. UBS Group assumed coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. lifted their target price on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $32.17.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $21.08 on Friday. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -7.24 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $23.77. The firm’s 50-day simple moving average is $18.47 and its 200 day simple moving average is $16.43.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same period in the prior year, the business earned ($0.63) EPS. The company’s revenue was up .0% on a year-over-year basis. As a group, research analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider directly owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares in the company, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 12.50% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of institutional investors have recently modified their holdings of the business. Intrust Bank NA boosted its holdings in Denali Therapeutics by 5.6% in the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock worth $184,000 after buying an additional 589 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Denali Therapeutics by 15.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares in the last quarter. Pier 88 Investment Partners LLC boosted its holdings in shares of Denali Therapeutics by 1.1% in the fourth quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after acquiring an additional 760 shares during the period. Tudor Investment Corp ET AL boosted its holdings in shares of Denali Therapeutics by 1.7% in the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after acquiring an additional 920 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in shares of Denali Therapeutics by 7.4% in the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock valued at $189,000 after purchasing an additional 930 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.